MYC is altered in 12.93% of diffuse large B-cell lymphoma patients with MYC Amplification present in 2.58% of all diffuse large B-cell lymphoma patients [4].

MYC Amplification is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 5 are closed. Of the trials that contain MYC Amplification and diffuse large B-cell lymphoma as inclusion criteria, 4 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [5].

MYC is altered in 4.85% of malignant solid tumor patients with MYC Amplification present in 4.11% of all malignant solid tumor patients [4].

MYC Amplification is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 4 are open and 3 are closed. Of the trials that contain MYC Amplification and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [5].

MYC is altered in 4.29% of medulloblastoma patients with MYC Amplification present in 5.68% of all medulloblastoma patients [4].

MYC Amplification is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain MYC Amplification and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

MYC is altered in 9.92% of breast carcinoma patients with MYC Amplification present in 7.3% of all breast carcinoma patients [4].

MYC Amplification is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MYC Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

MYC is altered in 6.64% of non-hodgkin lymphoma patients with MYC Amplification present in 1.63% of all non-hodgkin lymphoma patients [4].

MYC Amplification is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MYC Amplification and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

MYC is altered in 5.87% of lymphoma patients with MYC Amplification present in 1.43% of all lymphoma patients [4].

MYC Amplification is an inclusion criterion in 3 clinical trials for lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MYC Amplification and lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 3 clinical trials for mature B-cell lymphoma/leukemia, of which 1 is open and 2 are closed. Of the trials that contain MYC Amplification and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

MYC Amplification is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain MYC Amplification and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 4 (1 open) [5].

MYC is altered in 7.33% of ovarian carcinoma patients with MYC Amplification present in 7.28% of all ovarian carcinoma patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Amplification and ovarian carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

MYC is altered in 4.93% of colorectal carcinoma patients with MYC Amplification present in 4.24% of all colorectal carcinoma patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Amplification and colorectal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

MYC is altered in 4.84% of non-small cell lung carcinoma patients with MYC Amplification present in 4.11% of all non-small cell lung carcinoma patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 3.0% of central nervous system embryonal neoplasm patients with MYC Amplification present in 3.94% of all central nervous system embryonal neoplasm patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC is altered in 2.79% of follicular lymphoma patients with MYC Amplification present in 0.94% of all follicular lymphoma patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Amplification and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 0.7% of gastrointestinal stromal tumor patients with MYC Amplification present in 0.3% of all gastrointestinal stromal tumor patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain MYC Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MYC is altered in 1.82% of hodgkin lymphoma patients [4].

MYC Amplification is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for marginal zone lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Amplification and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MYC Amplification and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 2 clinical trials for transformed non-hodgkin lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Amplification and transformed non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (0 open) [5].

MYC is altered in 12.5% of large cell/anaplastic medulloblastoma patients with MYC Amplification present in 50.0% of all large cell/anaplastic medulloblastoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for large cell/anaplastic medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC is altered in 8.63% of esophageal adenocarcinoma patients with MYC Amplification present in 8.08% of all esophageal adenocarcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 8.92% of adenocarcinoma of the gastroesophageal junction patients with MYC Amplification present in 8.03% of all adenocarcinoma of the gastroesophageal junction patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 7.67% of hepatocellular carcinoma patients with MYC Amplification present in 7.46% of all hepatocellular carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 6.64% of osteosarcoma patients with MYC Amplification present in 6.99% of all osteosarcoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 5.87% of prostate carcinoma patients with MYC Amplification present in 5.03% of all prostate carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 5.13% of esophageal squamous cell carcinoma patients with MYC Amplification present in 4.59% of all esophageal squamous cell carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 5.49% of small cell lung carcinoma patients with MYC Amplification present in 4.58% of all small cell lung carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

MYC is altered in 4.85% of gastric adenocarcinoma patients with MYC Amplification present in 4.03% of all gastric adenocarcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 4.72% of solid neoplasm patients with MYC Amplification present in 3.99% of all solid neoplasm patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and solid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 4.7% of cancer patients with MYC Amplification present in 3.89% of all cancer patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 5.93% of endometrial carcinoma patients with MYC Amplification present in 2.92% of all endometrial carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 3.39% of mantle cell lymphoma patients with MYC Amplification present in 2.92% of all mantle cell lymphoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and mantle cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 2.53% of anaplastic astrocytoma patients with MYC Amplification present in 2.91% of all anaplastic astrocytoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 2.65% of biliary tract carcinoma patients with MYC Amplification present in 2.45% of all biliary tract carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 2.52% of soft tissue sarcoma patients with MYC Amplification present in 2.15% of all soft tissue sarcoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 7.91% of B-cell non-hodgkin lymphoma patients with MYC Amplification present in 1.87% of all B-cell non-hodgkin lymphoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 2.32% of head and neck squamous cell carcinoma patients with MYC Amplification present in 1.75% of all head and neck squamous cell carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 1.62% of diffuse glioma patients with MYC Amplification present in 0.98% of all diffuse glioma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.61% of malignant glioma patients with MYC Amplification present in 0.98% of all malignant glioma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.61% of glioblastoma patients with MYC Amplification present in 0.88% of all glioblastoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 0.9% of leiomyosarcoma patients with MYC Amplification present in 0.79% of all leiomyosarcoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 1.5% of papillary renal cell carcinoma patients with MYC Amplification present in 0.79% of all papillary renal cell carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 1.24% of central nervous system neoplasm patients with MYC Amplification present in 0.73% of all central nervous system neoplasm patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 0.68% of clear cell renal cell carcinoma patients with MYC Amplification present in 0.56% of all clear cell renal cell carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 0.8% of renal cell carcinoma patients with MYC Amplification present in 0.54% of all renal cell carcinoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 0.55% of neuroblastoma patients with MYC Amplification present in 0.29% of all neuroblastoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 0.62% of pleural mesothelioma patients with MYC Amplification present in 0.21% of all pleural mesothelioma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.86% of anaplastic oligodendroglioma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 64.29% of Burkitt lymphoma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for desmoplastic/nodular medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and double-hit lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and hairy cell leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 1.09% of high-grade glioma, NOS patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for intraocular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and intraocular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for medulloblastoma with extensive nodularity, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 1.9% of multiple myeloma patients [4].

MYC Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC Amplification and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and small lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Amplification is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Amplification and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].